A Phase 1 interventional study of Dulaglutide (Reference) and Dulaglutide (Test) in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-29.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate a new formulation of dulaglutide (study drug) administered under the skin as one injection using a single dose pen compared to three injections using a pre filled syringe.
This study will evaluate how much of the study drug enters the body and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.
The study will last about 84 days, including screening and will require overnight stays in the clinical research unit (CRU).
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dulaglutide 4.5 mg administered subcutaneously (SC) in 3 prefilled syringes (PFS) in one of two study periods
Drug: Dulaglutide (Reference)
Dulaglutide 4.5 mg administered SC in 1 single dose pen (SDP) in one of two study periods
Drug: Dulaglutide (Test)
Administered SC
Also known as: LY2189265
Administered SC
Also known as: LY2189265
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide
Pharmacokinetics was assessed in healthy participants to determine the area under the concentration time curve from 0 to infinity (AUC\[0-∞\]) of Dulaglutide.
Time frame: Periods 1 and 2: Day 1 - 8 and Day 15: Predose, 24, 48, 72,96,120,144,168, and 336 hours post dose; Follow Up: Day 28
PK: Maximum Observed Drug Concentration (Cmax) of Dulaglutide
Pharmacokinetics was assessed in healthy participants to determine the maximum observed drug concentration (Cmax) of Dulaglutide.
Time frame: Periods 1 and 2: Day 1 - 8 and Day 15: Predose, 24, 48, 72,96,120,144,168, and 336 hours post dose; Follow Up : Day 28
| Milestone | Sequence A Dulaglutide (Reference) Then Dulaglutide (Test) | Sequence B Dulaglutide (Test) Then Dulaglutide (Reference) |
|---|---|---|
| Started | 15 | 12 |
| Received at least one dose of study drug | 15 | 11 |
| Completed | 14 | 10 |
| Not completed | 1 | 2 |
| Withdrew: Adverse event | 1 | 2 |
| Milestone | Sequence A Dulaglutide (Reference) Then Dulaglutide (Test) | Sequence B Dulaglutide (Test) Then Dulaglutide (Reference) |
|---|---|---|
| Started | 14 | 10 |
| Received at least one dose of study drug | 12 | 9 |
| Completed | 10 | 9 |
| Not completed | 4 | 1 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
Pharmacokinetics was assessed in healthy participants to determine the area under the concentration time curve from 0 to infinity (AUC\[0-∞\]) of Dulaglutide.
| nanogram.hour/milliliter (ng.h/mL) | Dulaglutide (Reference) | Dulaglutide (Test) |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide | 37400 ± 38 | 40000 ± 33 |
Pharmacokinetics was assessed in healthy participants to determine the maximum observed drug concentration (Cmax) of Dulaglutide.
| nanogram/milliliter (ng/mL) | Dulaglutide (Reference) | Dulaglutide (Test) |
|---|---|---|
| PK: Maximum Observed Drug Concentration (Cmax) of Dulaglutide | 213 ± 41 | 240 ± 39 |
Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dulaglutide (Reference) | 0/24 (0%) | 0/24 (0%) | 15/24 (62.5%) |
| Dulaglutide (Test) | 0/23 (0%) | 0/23 (0%) | 14/23 (60.9%) |
| Event | Dulaglutide (Reference) | Dulaglutide (Test) |
|---|---|---|
| NauseaGastrointestinal disorders | 11/24 | 12/23 |
| VomitingGastrointestinal disorders | 5/24 | 7/23 |
| ConstipationGastrointestinal disorders | 4/24 | 3/23 |
| DizzinessNervous system disorders | 4/24 | 1/23 |
| HeadacheNervous system disorders | 3/24 | 1/23 |
| DyspepsiaGastrointestinal disorders | 2/24 | 2/23 |
| Injection site painGeneral disorders | 2/24 | 2/23 |
All randomized participants
| Age, Continuous(years) | Dulaglutide Test and Reference |
|---|---|
| Mean | 41.7 ± 10.5 |
| Sex: Female, Male(Participants) | Dulaglutide Test and Reference |
|---|---|
| Female | 12 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Dulaglutide Test and Reference |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 23 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Dulaglutide Test and Reference |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 22 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Dulaglutide Test and Reference |
|---|---|
| United States | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Jun 2018, 5 months.
Results were first posted in Jul 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide